NEW YORK (GenomeWeb News) – Genomic cancer test provider BioTheranostics today announced a contract with preferred provider network Prime Health Services for coverage of BioTheranostics' tests for breast cancer and metastatic disease.

Members of Prime Health now have access to San Diego-based BioTheranostics' molecular-based tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, and CancerType ID for diagnosing metastatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.